Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
2. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004;4:487-498.
3. WHO Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481-1495.
5. Briand S, Bertherat E, Cox P, et al. The international Ebola emergency. N Engl J Med. 2014;371:1180-1183.
6. Centers for Disease Control and Prevention. Infection Prevention and Control Recommendations for Hospitalized Patients Under Investigation (PUIs) for Ebola Virus Disease (EVD) in U.S. Hospitals. Available at https://www.cdc.gov/vhf/ebola/clinicians/evd/infection-control.html. Last accessed March 8, 2024.
7. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371:1418-1425.
8. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(Suppl 3):S810-S816.
9. Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for critically ill patients with Ebola virus disease: perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733-737.
10. Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinal Surveillance Network. Clin Infect Dis. 2007;44:1560-1568.
11. Funk DJ, Kumar A. Ebola virus disease: an update for anesthesiologists and intensivists. Can J Anesth. 2015;62:80-91.
12. Oestereich L, Ludtke A, Wurr S, Reiger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17-21.
13. Centers for Disease Control and Prevention. The 2014–2016 Ebola Outbreak in West Africa. Available at https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html. Last accessed March 8, 2024.
14. Edmond MB, Diekema DJ, Perencevich EN. Ebola virus disease and the need for new personal protective equipment. JAMA. 2014;312(23):2495-2496.
15. Gostin LO, Hodge JG, Burris S. Is the United States prepared for Ebola? JAMA. 2014;312(23):2497-2498.
16. Centers for Disease Control and Prevention. Ebola Virus Disease: Screening Patients. Available at https://www.cdc.gov/vhf/ebola/clinicians/evaluating-patients/index.html. Last accessed March 8, 2024.
17. Tambo E, Ugwu EC, Ngogang JY. Need of surveillance response systems to combat Ebola outbreaks and other emerging infectious diseases in African countries. Infect Dis Poverty. 2014;3:29.
18. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47-53.
19. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J. 1977;2(6086):541-544.
20. Centers for Disease Control and Prevention. Case Definition for Ebola Virus Disease (EVD). Available at https://www.cdc.gov/vhf/ebola/clinicians/evaluating-patients/index.html. Last accessed March 8, 2024.
21. Centers for Disorder Control and Prevention. Guidance for Collection, Transport and Submission of Specimens for Ebola Virus Testing. Available at https://www.cdc.gov/vhf/ebola/laboratory-personnel/specimens.html. Last accessed March 8, 2024.
22. Centers for Disease Control and Prevention. Ebola Virus Disease (EVD) Information for Clinicians in U. S. Healthcare Settings. Available at https://www.cdc.gov/vhf/ebola/clinicians/evd/clinicians.html. Last accessed March 8, 2024.
23. U.S. Food and Drug Administration. First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response. Available at https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health. Last accessed March 8, 2024.
24. World Health Organization. Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola. Available at https://www.who.int/publications/i/item/WHO-HIS-SDS-2014.4-Rev.1. Last accessed March 8, 2024.
25. U.S. Food and Drug Administration. FDA Allows Marketing of First Rapid Diagnostic Test for Detecting Ebola Virus Antigens. Available at https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-rapid-diagnostic-test-detecting-ebola-virus-antigens. Last accessed March 8, 2024.
26. Shultz JM, Baingana F, Nuria Y. The 2014 Ebola outbreak and mental health: current status and recommended response. JAMA. 2015;313(6):567-568.
27. Henao-Restrepo A, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster randomised trial. Lancet. 2015;386(9996):857-866.
28. Jamieson DJ, Uyeki TM, Callaghan WM, et al. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol. 2014;124(5):1005.
29. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375(15):1448.
30. Centers for Disease Control and Prevention. Interim Guidance for Management of Survivors of Ebola Virus Disease in U.S. Hospital Settings. Available at https://www.cdc.gov/vhf/ebola/clinicians/evaluating-patients/guidance-for-management-of-survivors-ebola.html. Last accessed March 8, 2024.
31. Centers for Disease Control and Prevention. 2014–2016 Ebola Outbreak in West Africa, Cost of the Epidemic. Available at https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html. Last accessed March 8, 2024.
32. Centers for Disease Control and Prevention. Infection Prevention and Control Recommendations for Hospitalized Patients with Known or Suspected Ebola Hemorrhagic Fever in U.S. Hospitals. Available at https://www.cdc.gov/vhf/ebola/clinicians/evd/infection-control.html. Last accessed March 8, 2024.
34. Baseler, L, Chertow DS, Johnson KM, et al. The pathogenesis of Ebola virus disease. Annu Rev Pathol Mech Dis. 2017;12:387-418.
35. U. S. Food and Drug Administration. FDA Approves First Treatment for Ebola Virus. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus. Last accessed March 8, 2024.
36. Jagadesh S, Sevalie S, Fatoma R, et al. Disability among Ebola survivors and their close contacts in Sierra Leone: a retrospective case-controlled cohort study. Clin Infect Dis. 2018;66:131-133.
37. Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola Virus Disease survivors: final report. N Engl J Med. 2017;377:1428-1437.
38. Munster VJ, Bausch DG, de Witt E, et al. Outbreaks in rapidly changing Central Africa: lessons from Ebola. N Engl J Med. 2018;379:1198-1201.
39. Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease) Prevention and Vaccine. Available at https://www.cdc.gov/vhf/ebola/prevention/index.html. Last accessed March 8, 2024.
40. Centers for Disease Control and Prevention. Ebola Vaccine: Information about Ervebo. Available at https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html. Last accessed March 8, 2024.
41. Centers for Disease Control and Prevention. Ebola Virus Disease Distribution Map: Cases of Ebola Virus Disease in Africa Since 1976. Available at https://www.cdc.gov/vhf/ebola/history/distribution-map.html. Last accessed March 8, 2024.
42. Erickson B, Rangel C, O'Keefe E. U.S. to Implement Ebola Monitoring Program at Airports as New Cases Reported in Africa. Available at https://www.cbsnews.com/news/ebola-monitoring-program-u-s-considering-as-new-cases-reported-in-africa. Last accessed March 8, 2024.
43. Centers for Disease Control and Prevention. Guidance for Collection, Transport and Submission of Specimens for Ebola Virus Testing. Available at https://www.cdc.gov/vhf/ebola/laboratory-personnel/specimens.html. Last accessed March 8, 2024.
44. Malenfant JH, Joyce A, Choi MJ, et al. Use of Ebola vaccine: expansion of recommendations of the Advisory Committee on Immunization Practices to include two additional populations—United States, 2021. MMWR. 2022;71(8):290-292.
45. Centers for Disease Control and Prevention. Ebola Disease: History of Ebola Disease Outbreaks. Available at https://www.cdc.gov/vhf/ebola/history/chronology.html. Last accessed March 8, 2024.
46. Centers for Disease Control and Prevention. Ebola Disease: Transmission. Available at https://www.cdc.gov/vhf/ebola/transmission/index.html. Last accessed March 8, 2024.
47. U.S. Food and Drug Administration. Ebola Zaire Vaccine, Live (ERVEBO), Product Information. Available at https://www.fda.gov/vaccines-blood-biologics/ervebo. Last accessed March 8, 2024.
48. National Institute of Allergy and Infectious Diseases. News Releases: Ebola Vaccine Regimens Safe, Immunogenic in Adults and Children. NIAD Participated in International PREVAC Consortium, December 14, 2022. Available at https://www.niaid.nih.gov/news-events/ebola-vaccine-regimens-safe-immunogenic-adults-and-children. Last accessed March 8, 2024.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.